New options under study, but for now anti-VEGF monotherapy remains gold standard for wet AMD

Anti-VEGF-A therapy will never completely go away for the treatment of neovascular age-related macular degeneration, but new therapies that improve the efficacy and durability of treatment are needed to help bridge the results between clinical data and real-life results for patients.VEGF-A suppression will not be abandoned, but researchers and ophthalmologists need to find a new way to increase efficacy and the durability of treatment to better serve patients diagnosed with wet AMD, OSN Retina/Vitreous Board Member Pravin U. Dugel, MD, said.